Nov 22, 2023
Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial
Nov 09, 2023
Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
Nov 06, 2023
Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer
Nov 02, 2023
Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer
Nov 01, 2023
Immutep to Participate in November Investor Events
